Research programme: integrase inhibitors - Bioflexis

Drug Profile

Research programme: integrase inhibitors - Bioflexis

Alternative Names: BFX 1001; BFX 1002; BFX 1003; BFX 1004; BFX 1005; BFX 1006; BFX 1007; BFX 1008

Latest Information Update: 16 Mar 2007

Price : $50

At a glance

  • Originator Bioflexis LLC
  • Class
  • Mechanism of Action Chelating agents; HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 27 Jan 2006 Preclinical trials in HIV infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top